

Symposium | Neurodevelopmental disorder : [Symposium 52] "Empowering Neurodiversity: Advancing Support for Adults with Developmental Disabilities"

📅 Fri. Sep 26, 2025 4:30 PM - 6:00 PM JST | Fri. Sep 26, 2025 7:30 AM - 9:00 AM UTC 🏢 Session Room 6  
(Conference Room B)

## [Symposium 52] "Empowering Neurodiversity: Advancing Support for Adults with Developmental Disabilities"

Moderator: Atsushi Kashiwa (Heart Clinic Medical Cooperation)

### [SY-52-04] Current Updates and Innovations in ADHD

\*Ahsan Nazeer<sup>1</sup> (1. Weill Cornell, NY, USA/ Sidra Medicine, Qatar (Qatar))

Keywords : ADHD, EndeavorRx, Viloxazine, Child and Adolescent Psychiatry, Adverse Childhood Experiences (ACEs)

---

Recent advancements in ADHD include new medication options, digital therapies, and deeper insights into the disorder's complexities. These include newer non-stimulant drugs like Viloxazine extended release and the first transdermal amphetamine patch, offering more personalized treatment choices. Digital therapies such as EndeavorRx, a video game-based approach, and the Monarch eTNS System are increasingly popular. Additionally, research is examining how ADHD exists on a spectrum with varying symptom severity along with the role of ACEs.